- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02269787
TeleMonitoring to Improve Substance Use Disorder Treatment After Detoxification
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Annually, about 25,000 Veterans receive inpatient detoxification (detox) for substance use disorders (SUDs). Detox is not SUD treatment; it is the medical management of withdrawal to prevent complications, which may be fatal. Detox inpatients who enter SUD treatment and peer-based mutual-help groups (e.g., Alcoholics Anonymous) have much better outcomes (less substance use, HIV/HCV risk behaviors, homelessness, rehospitalizations, Emergency Department visits) than those who do not. However, because of their unique characteristics (severe and chronic addictions, co-morbidities, lack of resources, self- and provider-perceptions as unsuitable for treatment), most Veterans discharged from inpatient detox do not enter SUD treatment. For many Veterans, a pattern of repeated inpatient detox, with each episode incurring a higher risk of overdose, occurs. Therefore, in its Uniform Services Handbook, Mental Health Operations places major emphasis on increasing the rate of SUD treatment initiation and engagement following detox to benefit Veterans' outcomes and prevent more use of costly health care.
The primary objective of this project is to implement and evaluate Enhanced Telephone Monitoring (ETM) as a new and innovative telehealth intervention to facilitate the transition from inpatient detox to SUD specialty treatment (residential, outpatient, pharmacotherapy), thereby improving Veterans' outcomes and decreasing VA health care costs. In a randomized trial at two sites (VA Palo Alto and Boston), investigators hypothesize that patients receiving ETM, compared to patients in usual care (UC), will be more likely to enter and engage in SUD treatment and mutual-help, have better SUD and related outcomes, and have fewer and delayed acute care episodes. This project will also conduct a formative evaluation of how to implement ETM VA-wide, focusing on diverse subgroups of Veterans. Further, it will conduct a Budget Impact Analysis (BIA) to determine the impact of ETM on total costs of VA care. Investigators hypothesize that the higher costs associated with ETM (because patients will engage in SUD treatment) will be more than offset by its lower costs of acute care.
Patients in the ETM condition will receive an in-person session while in detox, followed by coaching over the telephone for 3 months after discharge. The intervention will incorporate Motivational Interviewing, and Contracting, Prompting, and Reinforcing, to provide support while waiting for treatment, and facilitate entry into treatment and mutual-help, and improved responses to crises. Patients will be assessed at baseline and 3 and 6 months post-discharge for outcomes and non-VA health care; VA health care will be assessed with VA databases. GLMM analyses will be conducted to compare the UC and ETM groups on course of outcomes over time. The formative evaluation to inform the implementation of ETM will use the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework. Semi-structured interviews will be conducted with inpatient detox staff and patients to yield facilitators of ETM implementation and modifiable barriers with associated action plans. For the BIA, costs of ETM will be measured through microcosting methods. For patients in both the ETM and UC groups, all inpatient, residential, outpatient, and pharmacy care will be measured from VA utilization and cost files.
In summary, Mental Health Operations is committed to eradicating the dangerous, costly pattern of Veterans obtaining inpatient detox services but not receiving the SUD treatment they need. Telehealth interventions, a promising way to improve treatment access and outcomes by SUD patients, have not been utilized with the challenging population of detox inpatients before. In accordance with others in this CREATE, this project will help to accomplish Mental Health Operations' goal of implementing the Uniform Handbook by increasing Veterans' access to, engagement in, and benefit from, SUD treatment services, particularly among Veterans who are using VA medical services and need SUD services but are not receiving them.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
California
-
Palo Alto, California, Forenede Stater, 94304-1290
- VA Palo Alto Health Care System, Palo Alto, CA
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Beginning an episode of inpatient detoxification at the Boston or Palo Alto Veterans Affairs medical facilities, and
- have ongoing access to cell phone or land line telephone
Exclusion Criteria:
- Significant cognitive impairment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Enhanced Telephone Monitoring
Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
|
Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
Andre navne:
|
|
Ingen indgriben: Usual Care
Patients in the usual care condition will receive the care they would receive in the absence of a research project.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent of Participants Who Had an Additional Inpatient Detoxification
Tidsramme: 6-month follow-up
|
Percent that had (yes) an additional inpatient detoxification 6 months following baseline assessment- additional inpatient detoxification was dichotomous, yes or no.
|
6-month follow-up
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Christine Timko, PhD, VA Palo Alto Health Care System, Palo Alto, CA
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CRE 12-010
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Sædvanlig pleje
-
Xuzhou Medical UniversityIkke rekrutterer endnuIkke-invasiv CAR-T-celleovervågning | BCMA-målrettet PET-skanning | CAR-T-cellebiodistribution og -persistens | GMP-overensstemmende Radiopharmaka-præparation
-
The Affiliated Hospital of Xuzhou Medical UniversityRekrutteringCLL | SLL | CAR-T celleterapiKina
-
Duke UniversityNational Institutes of Health (NIH)RekrutteringHæmatopoietisk stamcelletransplantation | CAR-T celleterapiForenede Stater
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRekrutteringPatientrapporterede resultatmål | CAR T-celleterapiSchweiz
-
Patrick C. Johnson, MDRekruttering
-
University Health Network, TorontoIkke rekrutterer endnuLymfom, der modtager CAR-T-terapiCanada
-
The Lymphoma Academic Research OrganisationBristol-Myers Squibb; Novartis; Gilead SciencesRekrutteringHæmatopatologi kvalificeret eller CAR-t-cellebehandlingFrankrig
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutteringCAR-T Terapi KomplikationerItalien
-
Lara McKenzieAfsluttetIntervention-kuliltealarm + pædagogisk værktøj | Kontrol- Usual Care Flyer om kulilteForenede Stater
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Ikke rekrutterer endnuAllogen, CAR-T, proteinsekvestrering, ikke-genredigeretKina
Kliniske forsøg med Enhanced Telephone Monitoring
-
Biotronik Japan, Inc.Afsluttet
-
Hennepin Healthcare Research InstituteAfsluttetTraumatisk hjerneskadeForenede Stater
-
Bluedrop Medical LimitedAfsluttetDiabetisk fodForenede Stater
-
Medical University of ViennaAfsluttetIkke-traumatisk kompartmentsyndrom i benØstrig
-
Celero Systems, Inc.Afsluttet
-
Azienda Ospedaliero-Universitaria di ParmaRegione Emilia-RomagnaAfsluttetDiabetes mellitus, type 1Italien
-
LifeBridge HealthAmerican Heart Association (AHA)AfsluttetKoronararteriesygdom | Hjertefejl | Diabetes mellitusForenede Stater
-
University of Mississippi Medical CenterAfsluttetLungeventilation | KapnografiForenede Stater